ProCE Banner Activity

Experts Answer Frequently Asked Questions on the Contemporary Management of Hepatocellular Carcinoma

Conference Coverage
Clinical Thought
In this commentary, experts provide answers to questions from healthcare professionals on best practices in managing patients with HCC, with specific emphasis on the use of targeted and immunotherapies.

Released: January 03, 2022

Expiration: January 02, 2023

No longer available for credit.

Share

Faculty

Richard S. Finn

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Amit G. Singal

Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Mark Yarchoan

Mark Yarchoan, MD

Assistant Professor
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Richard S. Finn, MD, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, CStone, Eisai, Exelixis, Hengrui, Lilly, Merck, Novartis, Pfizer, and Roche/Genentech.

Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Amit G. Singal, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exact Sciences, Exelixis, Glycotest, GRAIL, Merck, Roche/Genentech, and Wako Diagnostics/FujiFilm Medical Sciences.

Mark Yarchoan, MD

Assistant Professor
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins
Baltimore, Maryland

Mark Yarchoan, MD, has disclosed that he has received consulting fees from AstraZeneca, Eisai, and Exelixis and funds for research support (paid to his institution) from Bristol-Myers Squibb, Exelixis, Genentech/Roche, and Incyte.